Cost analysis of noninvasive blood-based microRNA testing versus CT scans for follow-up in patients with testicular germ-cell tumors

Charytonowicz, Daniel, Aubrey, Harry, Bell, Chantelle, Ferret, Maeline, Tsui, Keith, Atfield, Rachel, Coleman, Nicholas, Murray, Matthew J. and Wilson, Edward C. F. ORCID: https://orcid.org/0000-0002-8369-1577 (2019) Cost analysis of noninvasive blood-based microRNA testing versus CT scans for follow-up in patients with testicular germ-cell tumors. Clinical Genitourinary Cancer, 17 (4). e733-e744. ISSN 1938-0682

Preview

PDF (Accepted_Manuscript) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

BACKGROUND: Our group has developed a noninvasive blood-based microRNA (miRNA) test for improving diagnosis, disease monitoring, and relapse detection in malignant testicular germ-cell tumors (TGCTs). Performance analysis suggests the test is likely to have comparable sensitivity and specificity in detecting TGCT as computed tomography (CT), thus reducing the need for serial CT scans for follow-up monitoring, with associated reductions in cumulative radiation burden and second cancer risk. To facilitate clinical adoption, we undertook a cost analysis to identify the budget impact of replacing CT scans with miRNA testing within health care systems. METHODS: The TGCT aftercare pathway was mapped out using National Comprehensive Cancer Network guidelines. A Markov model was built to simulate the impact of the miRNA test on TGCT aftercare costs. Incidence, treatment probabilities, relapse rate, and death rate data were collected from published studies to populate the model. RESULTS: Applying our model to the US health care system, the miRNA test has the potential to save up to $69 million per year in aftercare expenses related to TGCT treatment, with exact savings depending on the adoption rate and test price. CONCLUSION: This analysis demonstrates the potential positive budget impact of adopting miRNA testing in place of CT scans in the clinical management of TGCTs.

Item Type:	Article
Additional Information:	Copyright © 2019. Published by Elsevier Inc.
Uncontrolled Keywords:	genetics,costs and cost analysis,follow-up studies,economics,humans,male,markov chains,genetics,neoplasm staging,diagnosis,prognosis,survival analysis,diagnosis,economics,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Depositing User:	LivePure Connector
Date Deposited:	19 Mar 2019 11:30
Last Modified:	21 Oct 2022 22:31
URI:	https://ueaeprints.uea.ac.uk/id/eprint/70270
DOI:	10.1016/j.clgc.2019.03.015

Downloads

Actions (login required)

View Item